688321 Stock Overview
Shenzhen Chipscreen Biosciences Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shenzhen Chipscreen Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.55 |
| 52 Week High | CN¥25.99 |
| 52 Week Low | CN¥12.47 |
| Beta | 0.64 |
| 1 Month Change | -11.59% |
| 3 Month Change | -21.19% |
| 1 Year Change | -5.44% |
| 3 Year Change | n/a |
| 5 Year Change | -72.49% |
| Change since IPO | -68.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688321 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 4.9% | 2.6% | 3.5% |
| 1Y | -5.4% | -2.9% | 10.9% |
Return vs Industry: 688321 underperformed the CN Pharmaceuticals industry which returned -2.9% over the past year.
Return vs Market: 688321 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 688321 volatility | |
|---|---|
| 688321 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in CN Market | 11.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688321 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688321's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,187 | Xian-Ping Lu | www.chipscreen.com |
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; and chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor.
Shenzhen Chipscreen Biosciences Co., Ltd. Fundamentals Summary
| 688321 fundamental statistics | |
|---|---|
| Market cap | CN¥7.16b |
| Earnings (TTM) | -CN¥70.33m |
| Revenue (TTM) | CN¥656.24m |
10.9x
P/S Ratio-101.8x
P/E RatioIs 688321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688321 income statement (TTM) | |
|---|---|
| Revenue | CN¥656.24m |
| Cost of Revenue | CN¥81.86m |
| Gross Profit | CN¥574.37m |
| Other Expenses | CN¥644.70m |
| Earnings | -CN¥70.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 26, 2025
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 87.53% |
| Net Profit Margin | -10.72% |
| Debt/Equity Ratio | 78.4% |
How did 688321 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 09:31 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Chipscreen Biosciences Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhizhong Jing | China Merchants Securities Co. Ltd. |
| Bin Wu | China Merchants Securities Co. Ltd. |
| Yinglan Shu | Haitong International Research Limited |